Ask the Experts: Your Coverage Analysis & Billing Compliance Questions Answered
WCG Clinical
MARCH 28, 2024
The post Ask the Experts: Your Coverage Analysis & Billing Compliance Questions Answered appeared first on WCG.
coverage-analysis 
Beyond the Standard Coverage Analysis: Unpacking Challenging Billing Compliance Issues During Start-Up
WCG Clinical
MARCH 7, 2024
Part Two Slides Download The post Beyond the Standard Coverage Analysis: Unpacking Challenging Billing Compliance Issues During Start-Up appeared first on WCG.
Compliance 
52
52 Compliance 52
52 Join 32,000+
Insiders
Sign Up for our Newsletter
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Introduction to Coverage Analysis with Kelly Willenberg
Clinical Trial Podcast
APRIL 30, 2022
In this episode, we tackle another important aspect of clinical research finance, specifically, coverage analysis for US based clinical trials. At the beginning of any clinical trial, coverage analysis is generally required. Please join me in welcoming Kelly on the Clinical Trial Podcast.
Compliance 69
69 
Maximizing Study Start-up Efficiency – 8 Tips for Streamlining the Coverage Analysis Process
WCG Clinical
MARCH 17, 2023
With many clinical research sites facing study start-up delays and backlogs, performing a coverage analysis efficiently and thoroughly is critical to the study start-up process. But why is the coverage analysis process so vital for clinical trials and how can research sites do it more effectively?
Compliance 52
52 
Improving Research Billing Outcomes: The Real Impact of Coverage Analysis Choices
WCG Clinical
APRIL 28, 2023
WCG-Webinar-Slides-Improving-Research-Billing-Outcomes Download Does your coverage analysis align with the operational realities of billing for clinical trial services? Speak With Our Experts Contact Us The post Improving Research Billing Outcomes: The Real Impact of Coverage Analysis Choices appeared first on WCG Clinical.
Research 52
52 
What Sponsors Need to Know About Medicare Coverage Analysis
Advarra
MAY 26, 2023
With this focus, one of the five key areas identified for improving trial activation was creating Medicare Coverage Analysis (MCA, or National coverage analysis [NCA], as the paper stated) for industry-sponsored trials. The post What Sponsors Need to Know About Medicare Coverage Analysis appeared first on Advarra.
Coverage Analysis: Standard of Care vs What Medicare Covers
Forte Research Systems®
JULY 21, 2020
To address additional assessments outside the participant’s SOC, a coverage analysis is necessary. A patient’s standard of care refers to an item or service done as part of their routine care.
Global Multiple Myeloma Disease Coverage Forecast and Market Analysis 2021-2027 – ResearchAndMarkets.com
BioTech 365
APRIL 9, 2021
Global Multiple Myeloma Disease Coverage Forecast and Market Analysis 2021-2027 – ResearchAndMarkets.com Global Multiple Myeloma Disease Coverage Forecast and Market Analysis 2021-2027 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Multiple Myeloma Disease Coverage Forecast and Market Analysis” report has been (..)
Marketing 40
40 Marketing 40
40 
Prostate Cancer Disease Coverage Forecast and Market Analysis to 2036 – ResearchAndMarkets.com
BioTech 365
DECEMBER 11, 2020
Prostate Cancer Disease Coverage Forecast and Market Analysis to 2036 – ResearchAndMarkets.com Prostate Cancer Disease Coverage Forecast and Market Analysis to 2036 – ResearchAndMarkets.com DUBLIN–(BUSINESS WIRE)–The “Prostate Cancer Disease Coverage Forecast and Market Analysis to 2036” report has been added … (..)
Marketing 40
40 Marketing 40
40 
Seizure Disorder eDiary
WCG Clinical
MAY 25, 2023
Related Topics Clinical Trial Operational Excellence Clinical Endpoint Solutions Videos Most Recent Posts Why Biotech Sponsors Need Outside Support: IRB, IBC, DMCs and EACs More Guidance, Less Variability: Digital EDSS Givers Raters a More Precise, More User-Friendly Tool for MS Assessments Improving Research Billing Outcomes: The Real Impact of Coverage (..)
STAT+: Large health insurers lowered barriers to fair access to some drugs, analysis finds
STAT News
JANUARY 17, 2023
generally provide “fair access” to 19 treatments for a handful of serious diseases, although transparent coverage information is often lacking for some medicines, a new analysis found. Most of the largest health plans in the U.S.
Medicine 115
115 
Exposure to green space linked to reduced risk of postpartum depression
Medical Xpress
MARCH 7, 2023
In an analysis of more than 415,00 electronic health records of healthy, full-term births in Southern California, a team of researchers led by the University of California, Irvine, determined that exposure to green space and tree coverage was associated with a decreased risk of postpartum depression among mothers.
Research 75
75 Research 75
75 
Webinar: Communication and Training in a Multi-regional Setting
WCG Clinical
MARCH 16, 2023
Related Topics Clinical Trial Operational Excellence Patient Advocacy Diversity, Equity & Inclusion Videos Most Recent Posts Improving Research Billing Outcomes: The Real Impact of Coverage Analysis Choices Diversity Action Plans Will Soon Be Mandatory for Clinical Trials To Ensure Participant-Centered Recruitment, Ask the Right Questions Maximizing (..)
A new report brings telehealth fraud risk into focus
STAT News
SEPTEMBER 8, 2022
WASHINGTON — Washington’s attempts to permanently lock in telehealth coverage have been hobbled by a fear that virtual care could drive up Medicare fraud and spending. The analysis doesn’t account for the dollar amount of Medicare Advantage claims, but does include encounter data.
105 
Two million lost health coverage, thousands died prematurely in Trump’s first 3 years
Scienmag
OCTOBER 29, 2020
This contraction of coverage in 2016-19 caused as many as 25,180 excess deaths, even before COVID-19; if the Supreme Court overturns the Affordable Care Act, nearly 20 million Americans could lose coverage, resulting in up to 68,000 excess deaths A new analysis of federal surveys on health insurance coverage concludes that the number of uninsured Americans (..)
Medicine 54
54 Medicine 54
54 
UK bowel cancer screening uptake needs to increase to improve the survival rate
Pharmaceutical Technology
FEBRUARY 23, 2023
Currently, 70% of the population returns the completed home screening kit for analysis. There are also plans to lower the screening age to age 50 years by 2025, which will be a significant increase in screening coverage. The uptake of this home testing kit is improving over time.
Development 130
130 Development 130
130 
Health Canada grants approval for Moderna’s Covid-19 vaccine in children
Pharmaceutical Technology
JULY 15, 2022
Following two doses of the vaccine, initial efficacy analysis on PCR-confirmed cases during the Omicron wave showed efficacy estimates against Omicron in young children were in line with those in adults. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Vaccination 264
264 
West African nations need to ramp up COVID-19 vaccination 10-fold
Scienmag
DECEMBER 14, 2021
West African nations need to drastically ramp up their COVID-19 vaccination programmes by factor of 10 if they are to reach at least 60% coverage by 2022 and achieve the population level immunity needed to bring the pandemic under control in Africa and elsewhere, indicates an analysis published in the open access journal BMJ Global Health. […]. (..)
Vaccination 56
56 
What is Going on in Billing Compliance for Clinical Trials?
ACRP blog
JUNE 30, 2023
This should include coverage analysis; budget, contract, and consent review; participant registration and tracking; medical documentation for medical necessity; charge capture, segregation, and research pricing; Medicare Advantage commercial payers; and audit and review,” she said.
Compliance 111
111 
The futility of banner ads
World of DTC Marketing
AUGUST 30, 2022
Still, it wasn’t practical because physicians wanted much more information, including insurance coverage and compliance issues. I’ve done a lot of analysis of programmatic ad spending, and the fraud is unbelievably high, yet agencies continue to recommend programmatic.
Branding 270
270 
Anocca raises over $36 million for cancer cell therapy studies
Pharmaceutical Technology
MAY 31, 2023
Anocca’s platform features libraries of engineered human cells that allow for standardised analysis of T-cell biology, per the company’s website. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. Editorial content is independently produced and follows the highest standards of journalistic integrity.
Gene Therapy 130
130 
Eisai bites back against restricted coverage plan for Aduhelm
pharmaphorum
FEBRUARY 10, 2022
Japanese drugmaker Eisai has published comments filed with the US Centers for Medicare & Medicaid Services over its restrictive coverage proposal for beleaguered Alzheimer’s drug Aduhelm, saying it undermines well-established FDA processes. The post Eisai bites back against restricted coverage plan for Aduhelm appeared first on.
FDA Approval 58
58 
Five Tips for Improving Your Research Site’s Study Start-Up Timelines
ACRP blog
OCTOBER 4, 2023
For example, if two separate people complete the coverage analysis and budget, both need an understanding of the other document and process. If the budgeter does not know how to interpret a coverage analysis, they could easily budget incorrectly, which can lead to double billing and other major compliance concerns.
Research 59
59 
Beginner’s Guide to Budget Negotiation
Advarra
JANUARY 6, 2023
The process begins with a thorough review of the coverage analysis completed by the site and study documents provided by the sponsor (i.e., The coverage analysis outlines which items and services are billed to insurance and which items are paid for by the study sponsor. protocol, informed consent, and sponsor budget).
Five Tips for Improving Your Research Site’s Study Start-Up Timelines
ACRP blog
OCTOBER 4, 2023
For example, if two separate people complete the coverage analysis and budget, both need an understanding of the other document and process. If the budgeter does not know how to interpret a coverage analysis, they could easily budget incorrectly, which can lead to double billing and other major compliance concerns.
Research 52
52 
The current pricing of cancer treatments is unsustainable
World of DTC Marketing
NOVEMBER 24, 2021
According to an analysis published by JAMA Oncology, prices for new drugs approved for use in the treatment of cancer in the United States more than doubled over the past decade. The causes of financial ruin for cancer patients are many, including the high cost of treatments, filling in insurance coverage gaps and covering the loss of income.
Drugs 266
266 
What is Going on in Billing Compliance for Clinical Trials?
ACRP blog
JUNE 30, 2023
This should include coverage analysis; budget, contract, and consent review; participant registration and tracking; medical documentation for medical necessity; charge capture, segregation, and research pricing; Medicare Advantage commercial payers; and audit and review,” she said.
Compliance 52
52 
PanOmics: Advancing drug discovery
Drug Discovery World
OCTOBER 26, 2023
However, in-depth analysis of proteomics data can be challenging; it requires powerful computational tools and strong scientific expertise. One of the key advantages of ScreenPep is being able to benefit from high throughput without compromising coverage and accuracy. phosphorylations or ubiquitinations).
Drugs 52
52 
US starts review of Aduhelm coverage amid fears of Medicare hit
pharmaphorum
JULY 13, 2021
At the moment, the coverage for $56,000-a-year Aduhelm (aducanumab) is currently determined at the local level by Medicare administrative contractors representing 12 jurisdictions across the US, and that could lead to disparities in access and reimbursement.
Unmet needs in the obesity market
Pharmaceutical Technology
APRIL 13, 2023
GlobalData’s recent Obesity: Seven-Market Drug Forecast and Market Analysis report explores several of the unmet needs in this disease space. This is an important obstacle that needs to be overcome to optimise coverage for obesity. The obesity therapeutics market has considerable unmet needs.
Marketing 130
130 
How to identify and engage with digital opinion leaders
pharmaphorum
APRIL 19, 2022
Daily Newsletter – Coverage and analysis of all the latest industry headlines. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp’s privacy practices here. Subscription Options Extras.
Compliance 98
98 
At-home Self-testing: A Giant Leap Towards Transformation in Diagnostic Sector
Roots Analysis
JANUARY 16, 2023
At-home Self-testing has the ability to improve health equity and accelerate progress toward universal health coverage, and it has the capacity to alter health care. At-home Self-testing Kits – Grants Analysis. At-home Self-testing Kits – Demand Analysis. At-home Self-testing Kits – Market Forecast and Opportunity Analysis.
Bioassay 52
52 
5 best practices for improving patient engagement
pharmaphorum
MARCH 15, 2022
Daily Newsletter – Coverage and analysis of all the latest industry headlines. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp’s privacy practices here. Subscription Options Extras.
Life Science 98
98 
Playing an Active Role in Treatment Yields More Confidence in Patients
pharmaphorum
AUGUST 6, 2020
While there is no concrete definition, a meta-analysis of Health Union’s 2019 large scale, condition-specific In America surveys uncovers certain attitudes and behaviors associated with this mindset. But what does playing an active role in treatment really mean?
Marketing 52
52 Marketing 52
52 
Japan approves BMS’ Breyanzi for large B-cell lymphoma
Pharmaceutical Technology
DECEMBER 20, 2022
According to the interim analysis data from the trial, a statistically and clinically significant improvement in event-free survival (EFS), a primary endpoint, as well as progression-free survival (PFS) in subjects who received Breyanzi, were reported. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva.
Gene Therapy 147
147 
Medicines priced under the early access programme in France see prices drop by 16%
Pharmaceutical Technology
DECEMBER 15, 2022
Last year, the French National Authority for Health (HAS) expanded its remit (previously under the control of Agence nationale de sécurité du médicament et des produits de santé [ANSM]) to include early access authorisation decisions and related public funding coverage. Only 12% maintain their ATU/early access price for three years or more.
Medicine 147
147 
Leveraging augmented analytics to drive better business decisions
pharmaphorum
DECEMBER 21, 2021
Analysis frameworks provided by augmented analytics can help companies protect market share gains by adjusting for gaps in coverage. In use cases like the one above, companies can help grow market share by overlaying HCPs against sales coverage, which can be used to target underperforming HCPs.
Life Science 115
115 
What do companies need from COP27?
Pharmaceutical Technology
NOVEMBER 16, 2022
They are providing the data-led analysis you have come to expect from Energy Monitor but also something new: video interviews with business leaders, policymakers and campaigners. Other recent COP27 coverage includes: The interwoven fortunes of carbon markets and indigenous communities , by Oliver Gordon (16 November).
Marketing 130
130 
What do companies need from COP27?
Pharmaceutical Technology
NOVEMBER 16, 2022
They are providing the data-led analysis you have come to expect from Energy Monitor but also something new: video interviews with business leaders, policymakers and campaigners. Other recent COP27 coverage includes: The interwoven fortunes of carbon markets and indigenous communities , by Oliver Gordon (16 November).
Marketing 130
130 
Sorry, the Inflation Bill won’t lower healthcare costs
World of DTC Marketing
AUGUST 19, 2022
1ne: A new analysis predicts that by 2030, 48.9% Data from the Kaiser Family Foundation (KFF) shows that between 2011 and 2021, the average premiums for family coverage rose from $15,073 to $22,221—an increase of 47.4%. One in 4 U.S. adults has not taken their medication as prescribed due to cost. will be severely obese.
Drugs 204
204 
FTC Continues to Rage Against Device Patent Listings in the Orange Book
FDA Law Blog
MARCH 26, 2024
Unsurprisingly, the brief takes a trip through antitrust laws as well, explaining FTC’s position why such listings are anticompetitive, and, as part of that analysis addresses head-on FDA’s “ministerial role” with respect to the Orange Book.
Production 59
59 
Upcoming sickle cell gene therapies cost effective at $2 million, says ICER
Pharmaceutical Technology
APRIL 13, 2023
According to the report’s probabilistic sensitivity analysis, both therapies had a 0% probability of cost effectiveness at the threshold of $150,000 per QALY (and lower) from a healthcare system perspective. Cell & Gene Therapy coverage on Pharmaceutical Technology is supported by Cytiva. The treatments would have to cost $1.92
Gene Therapy 147
147 
Looking back at 2022: The top healthcare stories
Pharmaceutical Technology
DECEMBER 27, 2022
In a data-backed analysis, she further explored how the most number of designations are awarded to cancer drugs , and genetic disorders have the largest share of orphan therapies. Thank you for continuing to follow our coverage at Pharmaceutical Technology , Clinical Trials Arena and Medical Device Network. See you in 2023!
Clinical Trials 306
306 
Advancing stability in cell line development
Drug Discovery World
APRIL 15, 2024
At the intact level, monitoring PTMs can be accomplished by charge variant analysis. MS provides precise information about PTM localisation and protein structure through assays such as subunit analysis and peptide mapping. PTMs induce a shift in the isoelectric point (pI) of a molecule.
Development 59
59 
Let's personalize your content